Patents by Inventor Ronen EAVRI

Ronen EAVRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11918629
    Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 5, 2024
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Israel Nur, Elena Grimberg, Itai Podoler, Inbar Gahali-Sass, Erez Ilan, Ronen Eavri
  • Patent number: 11788146
    Abstract: A method for using bodily fluids in determining the cell-specific potency of drugs is provided. A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is also provided. Further, methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 17, 2023
    Assignee: BARCODE DIAGNOSTICS LTD.
    Inventors: Ronen Eavri, Annie Sabbah, Felix Badinter, Raphael Tshuva, Avi Schroeder
  • Patent number: 11712495
    Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: August 1, 2023
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11690937
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Publication number: 20230158119
    Abstract: Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.
    Type: Application
    Filed: January 12, 2023
    Publication date: May 25, 2023
    Inventors: INBAR GAHALI-SASS, ISRAEL NUR, EREZ ILAN, RONEN EAVRI
  • Patent number: 11654217
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: May 23, 2023
    Assignees: OMRIX BIOPHARMACEUTICALS LTD., ETHICON, INC.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 11583573
    Abstract: Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: February 21, 2023
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Inbar Gahali-Sass, Israel Nur, Erez Ilan, Ronen Eavri
  • Patent number: 11484623
    Abstract: The present invention is directed to a dry pad comprising pectin, a divalent cation and thrombin and to its preparation. Preferably, the density of pectin in the dry pad of the invention ranges from about equal to or higher than 1% to lower than 7% (w/v). The pad according to the invention comprises pectin having a low methoxyl content.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: November 1, 2022
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Erez Ilan, Yotam Gurman, Ronen Eavri, Elya Dekel
  • Publication number: 20210316048
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 14, 2021
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Publication number: 20210283056
    Abstract: A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is provided. Methods of predicting a response of a subject to a therapeutic agent using the composition, as well as methods of producing the composition are also provided.
    Type: Application
    Filed: July 4, 2019
    Publication date: September 16, 2021
    Inventors: Ronen EAVRI, Annie SABBAH, Felix BADINTER, Raphael TSHUVA, Avi SCHROEDER
  • Publication number: 20210228783
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 11045588
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 29, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Publication number: 20210154358
    Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
    Type: Application
    Filed: February 4, 2021
    Publication date: May 27, 2021
    Inventors: Erez ILAN, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11007301
    Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: May 18, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11007300
    Abstract: The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 18, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Patent number: 11000635
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 11, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 10960105
    Abstract: The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 30, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
  • Publication number: 20200216907
    Abstract: A method for using bodily fluids in determining the cell-specific potency of drugs is provided. A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is also provided. Further, methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.
    Type: Application
    Filed: July 5, 2018
    Publication date: July 9, 2020
    Inventors: Ronen EAVRI, Annie SABBAH, Felix BADINTER, Raphael TSHUVA, Avi SCHROEDER
  • Publication number: 20200188489
    Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 18, 2020
    Inventors: ISRAEL NUR, ELENA GRIMBERG, ITAI PODOLER, INBAR GAHALI-SASS, EREZ ILAN, RONEN EAVRI
  • Publication number: 20200188488
    Abstract: Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 ?M to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 18, 2020
    Inventors: INBAR GAHALI-SASS, ISRAEL NUR, EREZ ILAN, RONEN EAVRI